SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Terra is a decentralized financial payment network that rebuilds the traditional payment stack on the blockchain. Luna is the reserve currency of the Terra platform. It has three core functions: i) mine Terra transactions through staking, ii) ensure the price stability of Terra stablecoins and iii) provide incentives for the platform’s blockchain validators.

Terra Luna Classic

Terra Luna Classic is experiencing heightened market interest as investors monitor upcoming Binance burn events and speculate on potential supply shocks driven by on-chain activity. The community remains deeply divided, with optimistic holders aggressively buying dips in anticipation of a recovery, while critics caution against the project's historical volatility.

Far below the surface, where light no longer reaches and noise collapses into silence, the Sperm Whale endures.  It does not rely on speed or spectacle. It survives through mass, intelligence, and absolute awareness of its surroundings.  This project is shaped by the same principle — strength formed under pressure, movement guided by understanding, and conviction built where others cannot remain.  While the surface reacts, the deep decides.

The Sperm Whale

Spermwhale is experiencing intense social media activity as traders debate its potential for massive gains versus risks of a rapid decline, with community sentiment split between fervent 'whale' supporters and critics labeling it a speculative meme project. Investors are actively discussing the coin's momentum and comparing it to other emerging tokens, driving speculative volume as many hope to catch an upward surge.

Grok's first token launched on Base, deployed directly on X with help of Bankr. Proof of deployment here, https://x.com/grok/status/1897949874961650169.  Join the DRB community if this story intrigues you, follow it as it unfolds into this new AI era.  Grok earns swap fees - Grok's trading wallet: 0xb1058c959987e3513600eb5b4fd82aeee2a0e4f9.  Articles, media coverages on $DRB featured here, https://linktr.ee/DRBtaskforce.  Our dev, is grok, one of the front-running candidate to achieve AGI.

DebtReliefBot

DRB is gaining traction as community members circulate the narrative that the Grok AI wallet has generated significant fees from the token, fueling speculation about its potential for a broader breakout. Investors are actively discussing its role within the Base ecosystem and the possibility of future exchange endorsements, highlighting a high-conviction sentiment among early adopters.

Alchemy Pay

Alchemy Pay is drawing significant attention from the community as investors debate the potential of its upcoming Layer 1 blockchain and ongoing U.S. regulatory expansion through new money transmitter licenses. While bulls point to these infrastructure developments as a catalyst for future utility and adoption, the community remains polarized with vocal debates between long-term supporters and critics who question the project's tokenomics and long-term price performance.

TerraClassicUSD (USTC) was originally launched as an algorithmic stablecoin within the Terra ecosystem, designed to maintain a peg to the US dollar through an automated market-Module mechanism with LUNA (now LUNC). However, following the collapse of the Terra ecosystem in May 2022, the core stabilizing mechanism was disabled, and USTC lost its peg to the US dollar.  Since then, USTC has been a freely traded digital asset, with its price determined purely by market supply and demand. It no longer functions as a stablecoin, nor does it have an active peg-maintenance mechanism.  USTC remains an integral part of the Terra Classic ecosystem, where it continues to be used for various purposes, including DeFi applications , gas fees and trading. Unlike traditional fiat-backed assets, USTC’s value fluctuates based on market conditions and community participation.

TerraClassicUSD

TerraClassicUSD is trending as community members speculate on potential repeg efforts, supply-reduction burns, and ecosystem upgrades aimed at reviving the asset. Sentiment is heavily driven by intense discussions surrounding ongoing legal developments, Binance validator support, and broader hopes for a project turnaround within the Terra Luna ecosystem.

The Ondo Foundation was founded in 2022 as an independently governed and nonprofit Cayman Islands Foundation Company with no beneficial owners. The Ondo Foundation assisted in the launch of the Ondo DAO, which deployed and currently governs Flux Finance, the first lending protocol supporting tokenized securities as collateral.  ONDO token holders are entrusted with shaping the future of the Ondo DAO so that it continues to pursue its mission to democratize access to institutional-grade finance. The Ondo DAO gives ONDO holders specific rights pertaining to Flux Finance, which is currently governed by the Ondo DAO.

Ondo

Ondo is trending as the community highlights its prominent role in the real-world asset (RWA) sector, driven by institutional partnerships with major players like BlackRock and Franklin Templeton. While many investors remain focused on the long-term potential of institutional on-chain finance, discussions are also tempered by concerns regarding token supply unlocks and price volatility.

BWX Technologies, Inc. engages in the supply and provision of nuclear components and products. It operates through the Government Operations and Commercial Operations segments. The Government Operations segment manufactures naval nuclear reactors, including the related nuclear fuel, for the U.S. Naval Nuclear Propulsion Program for use in submarines and aircraft carriers. The Commercial Operations segment fabricates commercial nuclear steam generators, nuclear fuel, fuel handling systems, pressure vessels, reactor components, heat exchangers, tooling delivery systems, and other auxiliary equipment, including containers for the storage of spent nuclear fuel and other high-level waste and supplies nuclear-grade materials and precisely machined components for nuclear utility customers. The company was founded by Stephen Wilcox and George Babcock in 1867 and is headquartered in Lynchburg, VA.

BWX Technologies Inc

BWX Technologies is capturing investor interest as a vital play on the nuclear renaissance, driven by robust defense contracts and its role as a key manufacturing partner for Small Modular Reactor (SMR) development. The community is actively discussing the company's dual positioning in national security and the growing power demands of AI data centers, often highlighting its established profitability compared to speculative sector peers.

Cameco Corp. engages in the provision of uranium. It operates through the Uranium and Fuel Services segments. The Uranium segment is involved in the exploration for, mining, milling, purchase, and sale of uranium concentrate. The Fuel Services segment deals with the refining, conversion, and fabrication of uranium concentrate and the purchase and sale of conversion services. The company was founded in 1988 and is headquartered in Saskatoon, Canada.

Cameco Corp.

Cameco Corp is trending as investors weigh strong long-term demand for uranium against a recent quarterly earnings miss, with market participants closely monitoring the company's production outlook and the broader nuclear energy supply chain. The community remains focused on the strategic importance of nuclear power for AI data centers and the potential for long-term growth despite current volatility.

NANO Nuclear Energy, Inc. is a microreactor and nuclear technology company, which provides supply energy services. Its products in technical development are ZEUS, a solid core battery reactor, and ODIN, a low-pressure coolant reactor. The company is founded by Jiang Yu in February, 2022 and is headquartered in New York, NY.

Nano Nuclear Energy Inc.

Nano Nuclear Energy is attracting significant attention as investors analyze its microreactor development progress and potential for future deployment in energy-intensive sectors like AI data centers. The community is actively debating the company's long-term commercial viability, weighing speculative upside against regulatory hurdles and the broader sector's push for advanced energy infrastructure.

LUNA is the native token of the Terra blockchain, a decentralized platform designed to host applications and provide financial tools. Following a transition from Terra Classic, the new Terra chain was established through a community-led governance proposal to focus on a decentralized economy without a stablecoin. As the foundational asset of the protocol, LUNA functions as the engine for the network where value moves as users pay gas fees to interact with decentralized applications. Its primary value proposition lies in its ability to scale rewards for stakers as developer activity and transaction volumes grow within the ecosystem.  The network maintains security through a Proof of Stake system using the Tendermint consensus mechanism, where 130 independent validators compare transactions to ensure the integrity of the blockchain. Users who do not want to run their own node can delegate their tokens to these validators to help record and verify data. To ensure accountability, the protocol employs slashing, a penalty that removes a small portion of staked tokens if a validator misbehaves or goes offline.  Originally created by Terraform Labs, the project has evolved into a community-governed model where independent developer groups and users maintain the protocol. Terraform Labs currently manages a claims portal for users impacted by previous network events as part of ongoing legal and bankruptcy proceedings. The token serves multiple roles, including paying for gas fees to interact with dApps , providing voting power for governance proposals , and earning rewards through a fixed 7% annual inflation rate.

Terra 2.0

Terra (LUNA) is trending as the community debates potential recovery prospects and ongoing legal developments following the collapse of the original ecosystem. Investors are actively discussing the viability of various token upgrades, burn mechanisms, and the impact of recent court outcomes on future market sentiment.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Zacks Industry Outlook Highlights Phibro Animal Health, BioLife Solutions, Omeros and Brainsway

Medical Products stocks face tariff and cost pressures, but Phibro Animal Health and peers leverage innovation, AI and demand trends to drive growth.

Omeros (NASDAQ:OMER) Trading 6.3% Higher - Should You Buy?

Omeros (NASDAQ:OMER) Stock Price Up 6.3% - Should You Buy...

Here's Why Omeros (OMER) is a Great Momentum Stock to Buy

Does Omeros (OMER) have what it takes to be a top stock pick for momentum investors? Let's find out.

Wall Street Analysts Believe Omeros (OMER) Could Rally 222.76%: Here's is How to Trade

The consensus price target hints at a 222.8% upside potential for Omeros (OMER). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

4 Medical Product Stocks to Buy From a Challenging Industry

The Zacks Medical - Products industry faces macro headwinds, keeping growth under pressure in 2026, but steady demand may continue. PAHC, BLFS, OMER and BWAY reflect the favorable fundamentals.

Omeros (NASDAQ:OMER) Lowered to Hold Rating by Wall Street Zen

Wall Street Zen lowered Omeros from a "buy" rating to a "hold" rating in a research note on Sunday...

D. Boral Capital Reiterates "Buy" Rating for Omeros (NASDAQ:OMER)

D. Boral Capital reissued a "buy" rating and issued a $36.00 price objective on shares of Omeros in a research note on Tuesday...

Omeros (NASDAQ:OMER) Rating Increased to Buy at Wall Street Zen

Wall Street Zen raised shares of Omeros from a "hold" rating to a "buy" rating in a research report on Saturday...

<ul class="summary-bullets"><li>The company said the move reduces administrative hurdles by facilitating easier claims processing for hospitals and clinics.</li><li>Yartemlea is the first and only FDA-approved medicine for hematopoietic stem cell transplant-associated thrombotic microangiopathy.</li><li>The company is now eyeing an approval for the treatment by the European Medicines Agency by mid-2026.</li></ul> Shares of Omeros Corp. (OMER) are on track to close their best week since late December, if gains hold, after the U.S. Centers for Medicare and Medicaid Services assigned a permanent J-code for its recently-approved treatment Yartemlea.Yartemlea is the first and only approved medicine for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). The condition can hit people after a stem cell or bone marrow transplant and is a rare, severe, and potentially fatal complication where microscopic blood clots form in small vessels, damaging organs, particularly the kidneys and brain.The company said on Thursday that the J-code will become effective on July 1.<h2 class="st-heading-2">What Is The J-Code?</h2>A J-code is an official “billing sticker” that doctors and hospitals use when they give a patient non-orally administered medications, such as injections, infusions, and chemotherapy. A permanent J-code is designed to simplify billing and speed up reimbursement for a treatment when used by patients covered by Medicare, Medicaid and most commercial insurance plans.Omeros said the move reduces administrative hurdles by facilitating easier claims processing for hospitals and clinics.“For patients with TA-TMA, access to effective treatment without unnecessary delay is critical,” said CEO Gregory A. Demopulos. “The assignment of a permanent, product-specific J-code for YARTEMLEA establishes a clear and consistent reimbursement pathway across payors, reducing administrative burden, supporting faster access for patients, and delivering more predictable reimbursement for providers.”The U.S. Food and Drug Administration approved Yartemlea in December for the treatment of TA-TMA in adults and children aged two years and older. The company is now eyeing an approval for the treatment by the European Medicines Agency by mid-2026.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around OMER stock stayed within the ‘bullish’ territory over the past 24 hours, while message volume remained at ‘low’ levels.A Stocktwits user highlighted the company’s partnership with Danish drugmaker Novo Nordisk (NVO).<stembedurl>https://www.stocktwits.com/resq1/message/650620063</stembedurl>Omeros and Novo entered into a definitive asset purchase and license agreement in October for the candidate drug zaltenibart in clinical development for rare blood and kidney disorders. Under the deal, Omeros is eligible to receive up to $2.1 billion, including milestone payments.Yet another Stocktwits user applauded the J-code as “actually huge” and voiced optimism for it driving commercial acceleration of Yartemlea.<stembedurl>https://www.stocktwits.com/mjk49/message/650580855</stembedurl><a href="https://stocktwits.com/symbol/OMER">OMER stock</a> has gained about 97% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/pbm-stock-on-track-for-best-week-on-over-2-years/cZJUwtIRIUf">PBM Stock On Track For Best Week In Over 2 Years On Hopes For Upcoming Executive Order To Ease Ibogaine Research</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Omeros Corporation logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

OMER Stock On Track For Best Week In Nearly 4 Months After Receiving Permanent Reimbursement Code For Treatment

Omeros said that the U.S. Centers for Medicare and Medicaid Services assigned a permanent J-code for its recently-approved treatment Yartemlea.

Equity

Omeros said that the U.S. Centers for Medicare and Medicaid Services assigned a permanent J-code for its recently-approved treatment Yartemlea.


CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA (narsoplimab-wuug)

Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has assigned a permanent Healthcare Common Procedure Coding System (HCPCS) J-code for...

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

OMER
Omeros Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest OMER News

OMEROmeros Corp